Marker Therapeutics (MRKR) Competitors

Marker Therapeutics (NASDAQ:MRKR) and Elutia (NASDAQ:ELUT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, community ranking, risk, dividends, analyst recommendations, profitability, institutional ownership, media sentiment and earnings.

Which has higher valuation and earnings, MRKR or ELUT?

Marker Therapeutics has higher earnings, but lower revenue than Elutia. Marker Therapeutics is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marker Therapeutics	$6.59M	2.75	-$8.24M	-$1.33	-1.20
Elutia	$23.71M	3.09	-$37.66M	-$1.93	-0.92

Do analysts prefer MRKR or ELUT?

Marker Therapeutics presently has a consensus price target of $13.17, indicating a potential upside of 722.92%. Elutia has a consensus price target of $8.00, indicating a potential upside of 349.44%. Given Marker Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Marker Therapeutics is more favorable than Elutia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marker Therapeutics	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.50
Elutia	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media favor MRKR or ELUT?

In the previous week, Elutia had 4 more articles in the media than Marker Therapeutics. MarketBeat recorded 6 mentions for Elutia and 2 mentions for Marker Therapeutics. Elutia's average media sentiment score of 1.29 beat Marker Therapeutics' score of 0.93 indicating that Elutia is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Marker Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Elutia	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk & volatility, MRKR or ELUT?

Marker Therapeutics has a beta of 1.44, indicating that its share price is 44% more volatile than the S&P 500. Comparatively, Elutia has a beta of 0.86, indicating that its share price is 14% less volatile than the S&P 500.

Do institutionals and insiders believe in MRKR or ELUT?

22.4% of Marker Therapeutics shares are held by institutional investors. Comparatively, 74.0% of Elutia shares are held by institutional investors. 14.5% of Marker Therapeutics shares are held by insiders. Comparatively, 27.6% of Elutia shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Does the MarketBeat Community believe in MRKR or ELUT?

Marker Therapeutics received 63 more outperform votes than Elutia when rated by MarketBeat users. However, 100.00% of users gave Elutia an outperform vote while only 64.66% of users gave Marker Therapeutics an outperform vote.

Company	Underperform	Outperform
Marker Therapeutics	Outperform Votes 75 64.66%	Underperform Votes 41 35.34%
Elutia	Outperform Votes 12 100.00%	Underperform Votes No Votes

Is MRKR or ELUT more profitable?

Marker Therapeutics has a net margin of -179.74% compared to Elutia's net margin of -218.72%. Elutia's return on equity of 0.00% beat Marker Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Marker Therapeutics	-179.74%	-89.63%	-71.62%
Elutia	-218.72%	N/A	-142.61%

Summary

Marker Therapeutics and Elutia tied by winning 9 of the 18 factors compared between the two stocks.